Vol. 14 No. 4 Supplement, 2011

Table of Contents


Safety and Tolerability of Bevacizumab across Tumour Types

Full Article

M Kozloff

Hong Kong J Radiol 2011;14(Suppl):S4-11

Bevacizumab is one of the novel pharmacological agents used for the treatment of multiple tumour types including metastatic colorectal cancer, non–small-cell lung cancer, metastatic breast cancer, glioblastoma multiforme, and metastatic renal carcinoma.

The Evolving Role of Anti-angiogenic Agents for Ovarian Cancer Therapy

Full Article

RA Burger

Hong Kong J Radiol 2011;14(Suppl):S12-8

Angiogenesis, or the development of micro-vascular (blood and lymph) networks from established vasculature, is a process fundamental to proliferation, invasion and metastasis of ovarian cancer and other solid tumours.

The Role of Surgery in the Treatment of Ovarian Cancer

Full Article

KF Tam

Hong Kong J Radiol 2011;14(Suppl):S19-23

Most patients with ovarian cancer undergo surgery at some point during the course of their treatment. A primary operation may be undertaken for the purpose of confirming the diagnosis, staging, and debulking.

Evidence-based Management of Gastric Cancer

Full Article


Hong Kong J Radiol 2011;14(Suppl):S24-30

Gastric carcinoma is one of the most common cancers worldwide. Patients in the early stages of the disease experience non-specific symptoms. This contributes greatly to delayed diagnoses and poor prognoses, as reflected by low survival rates.

What is the Optimal Cytotoxic Regimen for Advanced Colorectal Cancer?

Full Article


Hong Kong J Radiol 2011;14(Suppl):S31-6

It is now well recognised that patients with metastatic colorectal cancer represent heterogeneous subgroups of patients with differing prognoses, because of differences in the number and sites of metastases, performance status, and the types of prior treatment.

Efficacy of Biological Therapies for the Treatment of Metastatic Colorectal Carcinoma

Full Article

NC Tebbutt

Hong Kong J Radiol 2011;14(Suppl):S37-45

Colorectal cancer is one of the most frequently diagnosed malignancies in the world. In Hong Kong, colorectal cancer is the second most common cancer and accounted for 16% of all new cancer cases in 2008.

Adjuvant Chemotherapy for High-risk Node-positive Breast Cancer: a Tale of Three Generations

Full Article

RKC Ngan

Hong Kong J Radiol 2011;14(Suppl):S46-55

Adjuvant chemotherapy for node-positive breast cancers has evolved a long way from the time-honoured nonanthracycline regimen of six cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) to the historical standard of anthracycline-based regimens

Management of Chronic Lymphocytic Leukaemia

Full Article

E Tse, H Singh Gill

Hong Kong J Radiol 2011;14(Suppl):S56-62

Chronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers

Rituximab in the Management of Follicular Lymphoma

Full Article

YL Kwong

Hong Kong J Radiol 2011;14(Suppl):S63-8

The incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most Asian populations. Follicular lymphoma is generally considered to be indolent with a life expectancy of approximately 10 to 14 years.

Haematopoietic Stem Cell Transplantation for Lymphoma

Full Article


Hong Kong J Radiol 2011;14(Suppl):S69-76

Recent advances in chemotherapy and chemoimmunotherapy have improved the outcomes of many lymphoma patients. However, patients with relapsed or refractory disease continue to have poor outcomes.

A Paradigm Shift in Non–small-cell Lung Carcinoma Treatment

Full Article


Hong Kong J Radiol 2011;14(Suppl):S77-83

The treatment paradigm of advanced non–small-cell lung carcinoma has evolved considerably owing to advances in molecular targeted therapy and the approval of two new classes of therapeutic agents, namely, epidermal growth factor receptor tyrosine-kinase inhibitors and angiogenesis inhibitors.